News

We would like to thank everyone who attended the pitch by our CSO, Dr.Nakayama, at ILS 2025, and all who visited our booth. We are delighted that so many of you showed interest in our work.
We will continue to drive forward our research and development with the aim of bringing innovative technologies into practical use. Please stay tuned for our future developments.

Keiichi Nakayama, our CSO, will be speaking at the ILS2025 Startup Pitch.
Please click here for more details about the presentation.

Our research project, "Preclinical Study of innovative Metabolic Inhibitors Targeting Refractory Cancers," has been selected for the Japan Agency for Medical Research and Development (AMED)'s "Program for an Innovative Cancer Therapy Development." AMED Official Release

The research project related to our company's R&D, titled "Identification and Development of Therapeutics for Cancer Stem Cells Using Non-Destructive Omics," has been selected by the Japan Agency for Medical Research and Development (AMED) for the FY2025 “Research Project for Accelerating Next-Generation Cancer Treatment ." AMED Official Release

We are advancing the development of inhibitors targeting three molecules involved in cancer cell proliferation and survival. The progress of each is introduced on this page. Please take a look.

Our CEO, Dr. Nishino, gave a presentation at the "International Open Innovation & Startup Symposium 2025" held on Wednesday, July 23, hosted by Institute of Science Tokyo. We would like to extend our sincere gratitude to everyone who attended the session. We remain committed to accelerating the development of innovative treatments for highly malignant cancers, and delivering them to patients as quickly as possible. (Check out the event highlights here)

Our CEO, Dr.Nishino, will be speaking at the "International Open Innovation & Startup Symposium 2025," hosted by Institute of Science Tokyo, on Wednesday, July 23. We would be honored if you could attend and listen to his talk.(For details, click here)

Our website has been updated, and now includes information on each of our pipelines. We encourage you to visit and explore the new content.

AntiCancer Technologies Inc. has opened official social media accounts to strengthen information dissemination. We will continue to share company initiatives and announcements.
・Facebook ・ LinkedIn・ X (formerly Twitter)・Instagram

We have been selected for the startup support program "NCC Seed Acceleration Program (NCC SAP)" hosted by the National Cancer Center Japan's Center for Translational Research. (For details, click here)

We have published research results obtained through the development of cancer immunotherapy and molecular targeted drugs in multiple peer-reviewed academic journals. A list of papers published since 2011 is reported here.

AntiCancer Technologies Inc. was selected as the 11th support destination for "1stRound," Japan's largest academia-co-sponsored entrepreneurship support program by The University of Tokyo's Collaborative Creation Platform Development Co., Ltd. (UTokyo IPC) (article here)

The achievements of the Nakayama Laboratory will be broadcast on BS Tokyo "Ima kara Science" (from 10 PM on Wednesday, June 19) (Click here for preview)

AntiCancer Technologies Inc. (Chiyoda-ku, Tokyo) conducted a third-party allotment capital increase with multiple angel investors as underwriters.

An introduction to AntiCancer Technologies Inc. was featured in Nikkei Biotech's "Venture Exploration" (Click here for the article)

Website opened.

Certified as a Tokyo Medical and Dental University Startup

Filed basic patent for Pipeline 1.

CSO Nakayama had a discussion with Mr. Takafumi Horie (See link)

Company established.